Sonnet BioTherapeutics Holdings, Inc. (SONN)

NASDAQ: SONN · IEX Real-Time Price · USD
1.860
-0.110 (-5.58%)
At close: Mar 28, 2024, 4:00 PM
1.820
-0.040 (-2.15%)
After-hours: Mar 28, 2024, 7:47 PM EDT

Company Description

Sonnet BioTherapeutics Holdings, Inc., a biotechnology company, owns a platform for biologic medicines of single or bifunctional action.

The company develops fully human albumin binding technology, which utilizes human single chain antibodies fragment that binds to and hitch-hikes on human serum albumin for transport to target tissues.

Its lead product candidate is SON-1010, a fully human single-chain version of interleukin 12 that is in Phase 1b/2a clinical trial for the treatment of solid tumor indications, including ovarian cancer, non-small cell lung cancer, and head and neck cancer.

The company is also developing SON-080, a fully human version of interleukin 6, which is in Phase 1b/I2a clinical trail to treat chemotherapy-induced peripheral neuropathy and diabetic peripheral neuropathy; and SON-1210, a bispecific compound for solid tumor indications, including colorectal cancer.

It has a license agreement with New Life Therapeutics Pte, LTD. to develop and commercialize pharmaceutical preparations containing a specific recombinant human interleukin-6.

The company is headquartered in Princeton, New Jersey.

Sonnet BioTherapeutics Holdings, Inc.
Sonnet BioTherapeutics Holdings logo
Country United States
Industry Biotechnology
Sector Healthcare
Employees 12
CEO Dr. Pankaj Mohan Ph.D.

Contact Details

Address:
100 Overlook Center, Suite 102
Princeton, New Jersey 08540
United States
Phone 609-375-2227
Website sonnetbio.com

Stock Details

Ticker Symbol SONN
Exchange NASDAQ
Fiscal Year October - September
Reporting Currency USD
CIK Code 0001106838
CUSIP Number 83548R105
ISIN Number US83548R3030
Employer ID 52-2102141
SIC Code 2834

Key Executives

Name Position
Dr. Pankaj Mohan Ph.D. Founder, Chairman, Chief Executive Officer and President
Dr. John K. Cini Ph.D. Chief Scientific Officer and Co-Founder
Jay Cross Chief Financial Officer
Donald J. Griffith CPA, CPA Controller and Director
Susan Dexter Chief Technical Officer
Dr. Richard T. Kenney FACP, M.D. Chief Medical Officer
Manuel Dafonseca Head of Clinical Operations

Latest SEC Filings

Date Type Title
Mar 11, 2024 8-K Current Report
Mar 6, 2024 8-K Current Report
Feb 14, 2024 8-K Current Report
Feb 14, 2024 10-Q Quarterly Report
Feb 1, 2024 8-K Current Report
Jan 29, 2024 8-K Current Report
Jan 4, 2024 EFFECT Notice of Effectiveness
Jan 2, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Dec 27, 2023 8-K Current Report
Dec 22, 2023 S-3 Registration statement under Securities Act of 1933